MedPath

The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals

Phase 4
Withdrawn
Conditions
Blood Pressure
Interventions
Registration Number
NCT01029223
Lead Sponsor
Bayside Health
Brief Summary

The purpose of this study is to determine the effect of slowing heart rate upon both central and peripheral blood pressures using a medication called Ivabradine which slows heart rate without affecting heart contraction, and to compare the effects of ivabradine to a traditional blood pressure lowering medication called metoprolol (which is a beta-blocker).

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Male
Target Recruitment
42
Inclusion Criteria
  • Aged 18 - 25 years OR
  • Aged > 60 years

Exclusion Criteria

  • Chronic disease
  • Unable to give informed consent
  • Treated or untreated systemic arterial hypertension (SBP > 160 mmHg and/or DBP > 90 mmHg)
  • Resting bradycardia (heart rate < 60 beats/minute)
  • Pregnancy or active lactation
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
placeboplacebo-
ivabradineivabradine-
metoprololmetoprolol-
Primary Outcome Measures
NameTimeMethod
central and peripheral arterial and pulse wave velocitybaseline, and 4 hours following the administration of placebo, metoprolol or ivabradine.
Secondary Outcome Measures
NameTimeMethod
Central pulse pressureBaseline measurements of central and peripheral arterial and pulse wave velocity will be made at baseline, and 4 hours following the administration of either placebo, metoprolol or ivabradine.
© Copyright 2025. All Rights Reserved by MedPath